Oppenheimer & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.4M | Sell |
22,477
-2,315
| -9% | -$1.77M | 0.21% | 91 |
|
|
2025
Q4 | $19.1M | Buy |
24,792
+1,078
| +5% | +$732K | 0.27% | 65 |
|
|
2025
Q3 | $13.3M | Buy |
23,714
+1,597
| +7% | +$903K | 0.16% | 130 |
|
|
2025
Q2 | $11.6M | Buy |
22,117
+3,974
| +22% | +$2.22M | 0.15% | 146 |
|
|
2025
Q1 | $11.5M | Buy |
18,143
+1,369
| +8% | +$942K | 0.17% | 129 |
|
|
2024
Q4 | $11.9M | Buy |
16,774
+7,029
| +72% | +$5.9M | 0.18% | 113 |
|
|
2024
Q3 | $10.2M | Sell |
9,745
-594
| -6% | -$661K | 0.16% | 143 |
|
|
2024
Q2 | $10.9M | Buy |
10,339
+80
| +0.8% | +$77.6K | 0.17% | 118 |
|
|
2024
Q1 | $9.87M | Sell |
10,259
-1,869
| -15% | -$1.78M | 0.16% | 136 |
|
|
2023
Q4 | $10.7M | Buy |
12,128
+1,139
| +10% | +$938K | 0.2% | 112 |
|
|
2023
Q3 | $9.04M | Sell |
10,989
-926
| -8% | -$728K | 0.19% | 120 |
|
|
2023
Q2 | $8.56M | Sell |
11,915
-325
| -3% | -$251K | 0.17% | 129 |
|
|
2023
Q1 | $10.1M | Sell |
12,240
-262
| -2% | -$198K | 0.21% | 100 |
|
|
2022
Q4 | $9.02M | Sell |
12,502
-429
| -3% | -$317K | 0.21% | 106 |
|
|
2022
Q3 | $8.91M | Sell |
12,931
-365
| -3% | -$230K | 0.21% | 104 |
|
|
2022
Q2 | $7.86M | Sell |
13,296
-1,816
| -12% | -$1.18M | 0.17% | 133 |
|
|
2022
Q1 | $10.6M | Sell |
15,112
-2,034
| -12% | -$1.29M | 0.19% | 111 |
|
|
2021
Q4 | $10.8M | Sell |
17,146
-870
| -5% | -$535K | 0.19% | 107 |
|
|
2021
Q3 | $10.9M | Buy |
18,016
+2,209
| +14% | +$1.37M | 0.2% | 103 |
|
|
2021
Q2 | $8.83M | Buy |
15,807
+3,404
| +27% | +$1.72M | 0.16% | 137 |
|
|
2021
Q1 | $5.87M | Buy |
12,403
+1,287
| +12% | +$627K | 0.12% | 203 |
|
|
2020
Q4 | $5.37M | Buy |
11,116
+698
| +7% | +$377K | 0.11% | 205 |
|
|
2020
Q3 | $5.83M | Buy |
10,418
+2,456
| +31% | +$1.49M | 0.15% | 145 |
|
|
2020
Q2 | $4.97M | Sell |
7,962
-2,218
| -22% | -$1.26M | 0.13% | 174 |
|
|
2020
Q1 | $4.97M | Buy |
10,180
+439
| +5% | +$181K | 0.15% | 140 |
|
|
2019
Q4 | $3.66M | Buy |
9,741
+2,508
| +35% | +$844K | 0.09% | 260 |
|
|
2019
Q3 | $2.01M | Sell |
7,233
-790
| -10% | -$234K | 0.05% | 389 |
|
|
2019
Q2 | $2.51M | Buy |
8,023
+1,212
| +18% | +$403K | 0.07% | 331 |
|
|
2019
Q1 | $2.8M | Sell |
6,811
-1,448
| -18% | -$596K | 0.07% | 311 |
|
|
2018
Q4 | $3.08M | Buy |
8,259
+109
| +1% | +$39.9K | 0.1% | 232 |
|
|
2018
Q3 | $3.29M | Sell |
8,150
-100
| -1% | -$38.1K | 0.08% | 270 |
|
|
2018
Q2 | $2.85M | Buy |
8,250
+1,988
| +32% | +$622K | 0.08% | 300 |
|
|
2018
Q1 | $2.16M | Buy |
6,262
+245
| +4% | +$85.2K | 0.06% | 376 |
|
|
2017
Q4 | $2.26M | Sell |
6,017
-1,738
| -22% | -$704K | 0.06% | 352 |
|
|
2017
Q3 | $3.47M | Buy |
7,755
+748
| +11% | +$356K | 0.09% | 258 |
|
|
2017
Q2 | $3.44M | Buy |
7,007
+1,199
| +21% | +$525K | 0.09% | 260 |
|
|
2017
Q1 | $2.25M | Buy |
5,808
+189
| +3% | +$70.1K | 0.06% | 351 |
|
|
2016
Q4 | $2.06M | Sell |
5,619
-115
| -2% | -$43.7K | 0.06% | 365 |
|
|
2016
Q3 | $2.31M | Sell |
5,734
-527
| -8% | -$211K | 0.07% | 333 |
|
|
2016
Q2 | $2.19M | Buy |
6,261
+76
| +1% | +$29.3K | 0.07% | 342 |
|
|
2016
Q1 | $2.23M | Sell |
6,185
-729
| -11% | -$300K | 0.07% | 325 |
|
|
2015
Q4 | $3.75M | Sell |
6,914
-469
| -6% | -$254K | 0.11% | 207 |
|
|
2015
Q3 | $3.43M | Sell |
7,383
-567
| -7% | -$304K | 0.1% | 219 |
|
|
2015
Q2 | $4.05M | Buy |
7,950
+319
| +4% | +$156K | 0.11% | 218 |
|
|
2015
Q1 | $3.44M | Sell |
7,631
-1,543
| -17% | -$654K | 0.09% | 250 |
|
|
2014
Q4 | $3.76M | Sell |
9,174
-716
| -7% | -$282K | 0.11% | 227 |
|
|
2014
Q3 | $3.57M | Buy |
9,890
+123
| +1% | +$41.2K | 0.11% | 232 |
|
|
2014
Q2 | $2.76M | Buy |
9,767
+298
| +3% | +$88.3K | 0.08% | 285 |
|
|
2014
Q1 | $2.84M | Sell |
9,469
-249
| -3% | -$76.7K | 0.09% | 286 |
|
|
2013
Q4 | $2.67M | Buy |
9,718
+214
| +2% | +$61.5K | 0.09% | 288 |
|
|
2013
Q3 | $2.97M | Sell |
9,504
-199
| -2% | -$52.3K | 0.1% | 243 |
|
|
2013
Q2 | $2.18M | Buy |
+9,703
| New | +$2.26M | 0.08% | 290 |
|
Other funds holding REGN
VCM
N
Oppenheimer & Co's REGN Position: Q1 2026 in Review
Oppenheimer & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 9.3% in Q1 2026, selling an estimated $1.77M and leaving 22,477 shares worth $17.4M. The position accounts for 0.21% of the portfolio, ranked #91.
Oppenheimer & Co first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.1M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Oppenheimer & Co held 22,477 shares of Regeneron Pharmaceuticals worth $17.4M as of Q1 2026.
- Oppenheimer & Co sold 2,315 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.77M.
- Regeneron Pharmaceuticals made up 0.21% of Oppenheimer & Co's portfolio in Q1 2026, its #91 holding.
- Oppenheimer & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Oppenheimer & Co's Regeneron Pharmaceuticals position peaked at $19.1M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.